Prelude wins FDA clearance for first KAT6A degrader trial

Prelude Therapeutics can start human testing of PRT13722, an oral KAT6A-selective degrader, after the FDA cleared its Investigational New Drug application for a Phase 1 study in HR-positive, HER2-negative breast cancer, with patient enrollment expected to begin in the fourth quarter of 2026.

"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," Charles Morris, MBChB, MRCP, chief medical officer of Prelude, said. "Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies may limit the utility in earlier lines of treatment."

The clearance removes the regulatory gate on the company's lead next-generation asset. The Phase 1 is a first-in-human, open-label, multicenter study measuring safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of PRT13722 both as a monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic disease. Prelude has not disclosed the planned patient count, dose-escalation design or trial site list.

The mechanism is the differentiator. KAT6A and KAT6B are histone acetyltransferases — enzymes that attach acetyl groups to histone proteins and thereby switch genes on. Dual inhibitors of both proteins have produced clinical responses in ER-positive breast cancer, but they hit KAT6B as well, and KAT6B suppression is associated with blood toxicity that stacks on top of what endocrine therapy and CDK4/6 inhibitors already do to bone marrow. Prelude's preclinical data indicate that degrading KAT6A while sparing KAT6B may widen the therapeutic window, which matters most in earlier lines of treatment where patients are already on a multi-drug backbone.

That is the commercial argument. Roughly 70% of breast cancers are HR-positive and HER2-negative, the largest subtype by far, and the standard first-line regimen pairs endocrine therapy with a CDK4/6 inhibitor such as Pfizer's Ibrance, Novartis's Kisqali or Eli Lilly's Verzenio. Those drugs extend progression-free survival but not indefinitely, and resistance emerges. A well-tolerated oral agent that can be layered onto the existing backbone without adding hematologic toxicity would address a patient population that dwarfs any niche indication — which is why KAT6 drew attention after dual-inhibitor data read out.

Prelude is not alone in pursuing it. Dual KAT6A/B inhibitors from larger players have already generated the clinical proof-of-concept that Morris cited, and those programs carry far more capital and trial infrastructure behind them. Prelude's bet is that selectivity beats breadth: a cleaner safety profile is worth more in combination settings than a stronger single-agent effect, because the combination is where the revenue is.

The company's pipeline also includes JAK2V617F mutant-selective inhibitors and preclinical work on degrader antibody conjugates, which pair its targeted protein degradation chemistry with antibody targeting. Prelude has not disclosed its cash position or runway in this announcement; the company's most recent quarterly filing is the reference point for how far that funding extends, and the Phase 1 start is the next scheduled milestone.

For investors, the clearance is a de-risking step, not a data event. PRLD is a clinical-stage micro-cap, and an IND clearance confirms the FDA accepted the preclinical package and the proposed protocol — it says nothing about whether PRT13722 works in humans or whether it is safe at therapeutic doses. The first real read on the program will be dose-escalation safety data, which typically arrives 12 to 24 months after first patient dosing. Between now and then, the stock's sensitivity runs to enrollment pace, any financing announcement, and the broader appetite for early-stage oncology names.

This article is for informational purposes only and does not constitute investment advice.